Pleural Effusion Drug Market Report 2026

The pleural effusion drug market size has grown strongly in recent years. It will grow from $3.32 billion in 2025 to $3.64 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases and lung infections, increasing incidence of heart failure-related pleural effusion cases, growing use of diuretics and antibiotics in hospital settings, expansion of critical care and emergency treatment infrastructure, rising awareness of early respiratory disease management.

The pleural effusion drug market size is expected to see strong growth in the next few years. It will grow to $5.31 billion by 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of targeted oncology therapies for malignant effusion, growth in precision medicine-based respiratory treatments, rising demand for minimally invasive drug delivery methods, expansion of homecare-based respiratory treatment solutions, increasing investment in biologics and advanced anti-inflammatory drugs. Major trends in the forecast period include precision medicine-based targeted therapy for pleural effusion management, biomarker-driven drug development for malignant pleural effusion treatment, advanced biologic anti-inflammatory therapies for fluid reduction in pleural space, increasing adoption of combination drug regimens for underlying cause treatment, development of long-acting injectable formulations for improved respiratory symptom control.

The rising burden of cardiovascular and heart failure diseases is expected to propel the growth of the pleural effusion drug market going forward. Cardiovascular diseases and heart failure are conditions in which the heart and blood vessels are damaged, resulting in complications such as heart attacks, stroke, and fluid buildup in the lungs. The burden of cardiovascular and heart failure diseases is increasing mainly due to aging populations, as age-related deterioration in heart and vascular function raises susceptibility to chronic cardiovascular conditions. Pleural effusion drugs help manage the burden of cardiovascular and heart failure diseases by reducing fluid accumulation in the pleural cavity, improving patient outcomes, and enhancing quality of life. For instance, in September 2025, according to the American College of Cardiology, a United States-based professional medical organization, deaths caused by cardiovascular diseases globally reached approximately 19.2 million in 2023, rising from 13.1 million in 2022. Therefore, the rising burden of cardiovascular and heart failure diseases is driving the growth of the pleural effusion drug market.

The rising healthcare expenditure is expected to propel the growth of the pleural effusion drug market going forward. Healthcare expenditure refers to the total amount spent by governments, insurers, and individuals on medical products, healthcare services, and public health activities. The increase in healthcare expenditure is primarily driven by an aging population and growing utilization of healthcare services, as higher demand for medical treatment leads to increased overall spending across public and private payers. The increasing healthcare expenditure directly supports the demand for pleural effusion drugs, as greater funding enables wider patient access to specialized medications and therapies used in the treatment of conditions such as pleural effusion. For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, in 2024, the UK’s healthcare spending reached approximately £317 billion, representing a 6.5% nominal increase compared with 2023. Therefore, the increasing healthcare expenditure is driving the growth of the pleural effusion drug market.

In October 2023, Aileron Therapeutics, Inc. acquired Lung Therapeutics, Inc. Through this acquisition, Aileron gained clinical-stage candidates such as LTI-01, a drug specifically developed for loculated pleural effusions, enabling the company to strengthen its pulmonary therapeutics pipeline and continue advancing these assets into 2024 and beyond. Lung Therapeutics, Inc. is a US-based biopharmaceutical company engaged in the development of drugs for pleural effusion.

Major companies operating in the pleural effusion drug market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Cipla Limited, Simcere Pharmaceutical Group Limited, Gongwin Biopharm Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Wuhan YZY Biopharma Co. Ltd., Lipac Oncology LLC, RS Oncology LLC, Genelux Corporation, Jiangxi Jemincare Group Co. Ltd., Biosyngen Pte. Ltd., Aileron Therapeutics Inc., Rusoma.

North America was the largest region in the pleural effusion drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pleural effusion drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pleural effusion drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pleural effusion drug market consists of sales of pleurodesis agents, corticosteroids, bronchodilators, and antifungal medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.